A composite score (CURB65-A) was created combining CURB65 classes with ProADM cut-offs to further risk-stratify patients.<br><b>RESULTS</b>: CURB65 and ProADM predicted both adverse events and mortality similarly well in CAP and non-CAP-LRTI.